Xiaoyan Yin, Wanqi Zhu, Xiaoyong Tang, Guangjian Yang, Xianguang Zhao, Kaikai Zhao, Liyang Jiang, Xiaolin Li, Hong Zhao, Xin Wang, Yuanyuan Yan, Ligang Xing, Jinming Yu, Xiangjiao Meng, Hanxi Zhao
BACKGROUND: The antiviral drug Nirmatrelvir was found to be a key drug in controlling the progression of pneumonia during the infectious phase of COVID-19. However, there are very few options for effective treatment for cancer patients who have viral pneumonia. Glucocorticoids is one of the effective means to control pneumonia, but there are many adverse events. EGCG is a natural low toxic compound with anti-inflammatory function. Thus, this study was designed to investigate the safety and efficacy of epigallocatechin-3-gallate (EGCG) aerosol to control COVID-19 pneumonia in cancer populations...
April 17, 2024: BMC Cancer